Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Gover...
April 20 2020 - 5:45PM
Biogen Releases 2019 Corporate Responsibility Report Demonstrating
Continuous Progress Across Environmental, Social and Governance
Metrics
Biogen Inc. (Nasdaq: BIIB) today released its 2019 Corporate
Responsibility Report that demonstrated continuous progress across
several environmental, social and governance (ESG) metrics. The
report outlines the company’s long-term commitment to corporate
responsibility by taking a multi-stakeholder approach to business
decisions, creating an inclusive culture, reducing its
environmental footprint and increasing reporting transparency on
ESG issues.
“In 2019 we continued to advance our health equity and diversity
goals while improving our environmental performance across energy,
water and waste metrics, and we are striving to do more,” said
Michel Vounatsos, Chief Executive Officer at Biogen. “Today, as we
collectively face the challenges posed by the global COVID-19
pandemic, the importance of developing and assuring access to new
therapies for patients in need is more evident than ever. For us,
that includes our aim of accelerating innovation, and at the same
time reducing our environmental footprint and contributing to a
more sustainable future for all of our stakeholders.”
As the first company in the life sciences industry to be carbon
neutral, Biogen has continued to be recognized as an environmental
leader, and is committing to bring its climate programs in line
with Intergovernmental Panel on Climate Change (IPCC) targets to
keep the global temperature rise to below 1.5˚Celsius. In 2019 the
company realized an absolute reduction of water use by nearly 3
percent, hazardous and nonhazardous waste by more than 7 percent,
supply chain emissions by 3 percent and non-renewable energy by 1.6
percent, all while increasing full year total revenues by 7 percent
versus the prior year.
Among other report highlights, Biogen advanced health equity
goals for its clinical trials to help better meet the needs of
underserved patients globally and continued to offer its early
access program to treat patients. The company also made progress
towards its goals for diversity and inclusion in the workplace,
with nearly 1/3 of director-level positions and above held by
people from racial and ethnic minority groups in the U.S. as of
December 31, 2019.
Building on the company’s 2019 community engagement efforts, the
Biogen Foundation committed $10 million for COVID-19 relief,
including $4 million to non-profit organizations and health systems
in Massachusetts, to address urgent needs, expand testing and help
ease the burden on health systems across Massachusetts, North
Carolina, the U.S. and the rest of the world. For several
non-profit organizations and health systems, the Biogen
Foundation’s support was the first to be received and helped
catalyze significant additional funds. Biogen employees have also
donated more than $300,000 to non-profit organizations and are
volunteering in their communities.
Our Corporate Responsibility Report can be found by visiting our
Year in Review website.
About BiogenAt Biogen, our mission is clear: we
are pioneers in neuroscience. Biogen discovers, develops and
delivers worldwide innovative therapies for people living with
serious neurological and neurodegenerative diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners
Walter Gilbert and Phillip Sharp. Today Biogen has the leading
portfolio of medicines to treat multiple sclerosis, has introduced
the first approved treatment for spinal muscular atrophy,
commercializes biosimilars of advanced biologics and is focused on
advancing research programs in multiple sclerosis and
neuroimmunology, Alzheimer’s disease and dementia, neuromuscular
disorders, movement disorders, ophthalmology, immunology,
neurocognitive disorders, acute neurology and pain.
We routinely post information that may be important to investors
on our website at www.biogen.com. To learn more, please visit
www.biogen.com and follow us on social media – Twitter, LinkedIn,
Facebook, YouTube.
About the Biogen Foundation The Biogen
Foundation supports access to science education and to essential
human services for children and their families in the communities
in which Biogen facilities are located. The Biogen Foundation is
committed to sparking a passion for science and discovery,
supporting effective science education initiatives and
strengthening efforts to make science education and science careers
accessible to diverse populations.
Biogen Safe HarborThis news release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, about our strategy and plans; and our ability
to achieve our ESG goals, commitments and targets. These statements
may be identified by words such as “aim,” “anticipate,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,”
“plan,” “possible,” “potential,” “will,” “would” and other words
and terms of similar meaning. You should not place undue reliance
on these statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation the risks of
unexpected hurdles, costs or delays; uncertainty of success in the
execution of our strategy and plans; the direct and indirect impact
related to the effect of COVID-19 on our business and operations,
including sales, expenses, supply chain, manufacturing, research
and development costs, clinical trials and employees; and the risks
and uncertainties that are described in the Risk Factors section of
our most recent annual or quarterly report and in other reports we
have filed with the U.S. Securities and Exchange Commission. The
foregoing sets forth many, but not all, of the factors that could
cause actual results to differ from our expectations in any
forward-looking statement. Investors should consider this
cautionary statement, as well as the risk factors identified in our
most recent annual or quarterly report and in other reports we have
filed with the U.S. Securities and Exchange Commission. These
statements are based on our current beliefs and expectations and
speak only as of the date of this news release. We do not undertake
any obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or
otherwise.
MEDIA CONTACT :David Caouette+ 1 617 679
4945public.affairs@biogen.com |
INVESTOR CONTACT:Joe Mara+1 781 464 2442IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biogen (TG:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024